HS
Harshit Srivastava
About Harshit Srivastava
Data last updated:
Harshit Srivastava is a Designated Partner at Medicare Pharma Plus Llp (since 2021). The companies operate in Business Services and Packaging. Earlier, Harshit Srivastava was a Director at Jbv Industries Private Limited (2017–2018) and Director at Jbvpackaging And Marketing Private Limited (from 2019).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Designated Partner | 01 Jul 2021 | 2021 | Active |
Previous companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Director | 18 Apr 2017 | 2017 | ₹1.09 Cr (FY 2020) | Active | |
| Director | 22 Jan 2019 | 2018 | ₹5.8 Lakh (FY 2022) | Strike Off |
Explore Director's current and past company associations Uncover their professional journey today!
Board colleagues of Harshit Srivastava
| Name | DIN | Company | Designation |
|---|---|---|---|
| Guru Lal Baksh | 07979264 | Medicare Pharma Plus Llp | Designated Partner |
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Harshit Srivastava
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Harshit Srivastava
Harshit Srivastava currently holds 1 directorship: Medicare Pharma Plus Llp (Designated Partner, since 01 Jul 2021).
Harshit Srivastava was first appointed on 18 Apr 2017 as Director at Jbv Industries Private Limited. The most recent appointment on record is 01 Jul 2021 at Medicare Pharma Plus Llp.
Harshit Srivastava held 2 earlier board appointments: Jbv Industries Private Limited (Director, 18 Apr 2017 to 16 Aug 2018); Jbvpackaging And Marketing Private Limited (Director, from 22 Jan 2019).
The current boards of Harshit Srivastava's companies include Guru Lal Baksh (Medicare Pharma Plus Llp).